Published in Medicine and Law Weekly, December 22nd, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Aeterna Zentaris.
Report 1: Aeterna Zentaris, Inc., (AEZ; AEZS) a growing global biopharmaceutical company focused on endocrine therapy and oncology, announced that its board of directors has approved the convening of a special meeting of shareholders on December 15, 2006 for the purpose of submitting to shareholders for their approval a resolution authorizing the distribution of all 11,052,996 subordinate voting shares of Atrium Biotechnologies held by Aeterna Zentaris by way of reduction...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly